{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T04:55:51Z","timestamp":1775796951954,"version":"3.50.1"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Nirsevimab was incorporated into the universal infant immunization schedule in October 2023. While its effectiveness during the first season has been described, real-world data on the second season and its impact on other respiratory virus hospitalizations are still limited, though more studies are likely to forthcoming. We aimed to evaluate the effect of nirsevimab implementation on hospital and PICU admissions for acute lower respiratory tract infections, including respiratory syncytial virus (RSV) and non-RSV etiologies, in children under 5 years of age with a specific focus on the second postintroduction season.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This retrospective study was conducted at a tertiary center in Tarragona, Spain. We included children under 5 hospitalized with acute lower respiratory tract infections (ALRTI) during the RSV seasons between 2018 and 2025 (excluding the 2020\u20132021 season due to the coronavirus disease pandemic). Demographic data, length of hospital stay, pediatric intensive care unit [PICU] stay and need for ventilatory support, were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Among 1384 ALRTI hospitalizations, 661were RSV-confirmed and 375 required PICU admission. After nirsevimab rollout, hospital admissions due to RSV decreased from 5.04 to 2.5 per 1000 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001), hospitalizations due to non-RSV decreased from 5.1 to 3.54 per 1000 children &lt;5 years (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.004) and PICU admissions due to ALRTI (RSV and non-RSV) declined from 2.9 to 1.3 per 1000 children (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). No differences were observed between the first and second postimplementation seasons in hospitalization, need for respiratory support, PICU or length of stay.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Universal nirsevimab immunization was associated with sustained reductions in RSV-related hospitalizations and critical illness, but also in hospitalizations due to other respiratory viruses.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/inf.0000000000005059","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T05:01:00Z","timestamp":1763614860000},"page":"393-398","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Impact of Nirsevimab in Its Second Season on Respiratory Syncytial Virus and Non-RSV Admissions in Children Under 5"],"prefix":"10.1097","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1696-036X","authenticated-orcid":false,"given":"Ester","family":"Parada-Ricart","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain"},{"name":"Department of Medicine and Surgery, Universitat Rovira I Virgili, Reus, Spain"},{"name":"Pediatric, Nutrition and development Research Unit (PEDINUR), IISPV, Tarragona, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N\u00faria","family":"Lled\u00f3-Gras","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain"},{"name":"Department of Medicine and Surgery, Universitat Rovira I Virgili, Reus, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Aragon\u00e8s-Zabalza","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain"},{"name":"Department of Medicine and Surgery, Universitat Rovira I Virgili, Reus, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Paima-Miguel","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Aparisi-Esteve","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Rodriguez-Hidalgo","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Zarauza-Pellejero","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Vi\u00f1as-Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria del Mar","family":"Alb\u00fajar-Font","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain"},{"name":"Department of Medicine and Surgery, Universitat Rovira I Virgili, Reus, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"key":"R1-20260410","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis.","volume":"399","author":"Li","year":"2022","journal-title":"Lancet"},{"key":"R2-20260410","doi-asserted-by":"crossref","first-page":"113932","DOI":"10.1016\/j.jpeds.2024.113932","article-title":"Disrupted seasonality of respiratory viruses: retrospective analysis of pediatric hospitalizations in Italy from 2019 to 2023.","volume":"268","author":"Palmas","year":"2024","journal-title":"J Pediatr"},{"key":"R3-20260410","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12916-025-03888-4","article-title":"Understanding the local-level variations in seasonality of human respiratory syncytial virus infection: a systematic analysis.","volume":"23","author":"Ye","year":"2025","journal-title":"BMC Med"},{"key":"R4-20260410","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S2352-4642(22)00321-2","article-title":"Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.","volume":"7","author":"Sim\u00f5es","year":"2023","journal-title":"Lancet Child Adolesc Health"},{"key":"R5-20260410","doi-asserted-by":"crossref","first-page":"209","DOI":"10.15585\/mmwr.mm7309a4","article-title":"Early estimate of nirsevimab effectiveness for prevention of respiratory syncytial virus\u2013associated hospitalization among infants entering their first respiratory syncytial virus season\u2014new vaccine surveillance network, October 2023\u2013February 2024.","volume":"73","author":"Moline","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R6-20260410","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/archdischild-2024-327153","article-title":"Effectiveness of nirsevimab immunoprophylaxis against respiratory syncytial virus-related outcomes in hospital and primary care settings: a retrospective cohort study in infants in Catalonia (Spain).","volume":"109","author":"Coma","year":"2024","journal-title":"Arch Dis Child"},{"key":"R7-20260410","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa2309189","article-title":"Nirsevimab for prevention of hospitalizations due to RSV in infants.","volume":"389","author":"Drysdale","year":"2023","journal-title":"N Engl J Med"},{"key":"R8-20260410","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2352-4642(25)00093-8","article-title":"Real-world effectiveness of nirsevimab against respiratory syncytial virus disease in infants: a systematic review and meta-analysis.","volume":"9","author":"Sumsuzzman","year":"2025","journal-title":"Lancet Child Adolesc Health"},{"key":"R9-20260410","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1001\/jamapediatrics.2024.5572","article-title":"Respiratory syncytial virus disease burden and nirsevimab effectiveness in young children from 2023-2024.","volume":"179","author":"Moline","year":"2025","journal-title":"JAMA Pediatr"},{"key":"R10-20260410","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1056\/NEJMoa2110275","article-title":"Nirsevimab for prevention of RSV in healthy late-preterm and term infants.","volume":"386","author":"Hammitt","year":"2022","journal-title":"N Engl J Med"},{"key":"R11-20260410","doi-asserted-by":"crossref","first-page":"e250380","DOI":"10.1001\/jamanetworkopen.2025.0380","article-title":"Estimated effectiveness of nirsevimab against respiratory syncytial virus.","volume":"8","author":"Xu","year":"2025","journal-title":"JAMA Netw Open"},{"key":"R12-20260410","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S2352-4642(25)00102-6","article-title":"180-day efficacy of nirsevimab against hospitalisation for respiratory syncytial virus lower respiratory tract infections in infants (HARMONIE): a randomised, controlled, phase 3b trial.","volume":"9","author":"Munro","year":"2025","journal-title":"Lancet Child Adolesc Health"},{"key":"R13-20260410","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1913556","article-title":"Single-dose nirsevimab for prevention of RSV in preterm infants.","volume":"383","author":"Griffin","year":"2020","journal-title":"N Engl J Med"},{"key":"R14-20260410","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/oxfordjournals.aje.a120955","article-title":"Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.","volume":"89","author":"Kim","year":"1969","journal-title":"Am J Epidemiol"},{"key":"R15-20260410","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/jpids\/piad113","article-title":"Infants receiving a single dose of nirsevimab to prevent RSV do not have evidence of enhanced disease in their second RSV season.","volume":"13","author":"Dagan","year":"2024","journal-title":"J Pediatr Infect Dis Soc"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000005059","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T04:01:35Z","timestamp":1775793695000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000005059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000005059","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,20]]}}}